German life science and technology company Merck KGaA is investing around €13 million, equivalent to more than ₹140 crore, to expand its manufacturing facility at Jigani in Bengaluru, strengthening India’s capabilities in biological buffers, specialty chemicals and other advanced life-science materials.
The expansion adds biological buffer manufacturing to the existing chemistry capabilities at the Jigani site. The facility is designed to support customer requirements ranging from research and development and process scale-up to commercial production, strengthening Merck’s regional manufacturing network across India and the Asia-Pacific region.
Key Project Details
| Parameter | Details |
|---|---|
| Company | Merck KGaA |
| Sector | Life Sciences / Pharmaceutical Manufacturing |
| Location | Jigani, Bengaluru, Karnataka |
| Investment | €13 million — over ₹140 crore |
| Existing site | Operational since 2003 |
| Site area | 10 acres |
| New capability | Biological buffer manufacturing |
| Applications | R&D, scale-up and commercial production |
| Existing capabilities | Specialty chemicals, fine chemicals, custom synthesis and catalogue products |
| New reactors | Four 5,000-litre reactors |
| Buffer & fine-chemical capacity | 100–300 MT annually |
| Employment | Specific new-job figure not disclosed |
Expansion Adds Biological Manufacturing Capability
The most important element of the investment is the addition of biological buffer manufacturing. These materials are used across areas including research, diagnostics, biotechnology and biopharmaceutical manufacturing.
Merck’s expanded Jigani operation is intended to combine biology and chemistry capabilities at the same manufacturing location, allowing the company to support customers through different stages of product development — from R&D and scale-up to commercial manufacturing.
Merck’s own facility information highlights four new 5,000-litre reactors, including Hastelloy and glass-lined systems. The expanded site also has in-house R&D and process-development capabilities and annual capacity of around 100–300 MT for buffers and fine chemicals.
10-Acre Manufacturing Campus
The Jigani facility has been operational since 2003 and occupies approximately 10 acres. Its existing manufacturing portfolio includes specialty and fine chemicals, custom synthesis and catalogue products.
The site also houses a microbiology application and training laboratory, a stable-isotope manufacturing operation developed in collaboration with the Department of Atomic Energy, and a temperature-controlled distribution centre.
The expanded campus therefore represents more than a single new production line. It is evolving into an integrated life-science manufacturing platform covering multiple chemistry and biology-related capabilities.
Strengthening India’s Life-Science Manufacturing Base
Merck said the investment is intended to strengthen regional manufacturing and expand its biology and chemistry capabilities across India and the Asia-Pacific region.
Dhananjay Singh, Managing Director of Merck’s Life Science business in India, described India as an increasingly important hub for life-science manufacturing. The company said the investment will also reinforce its global supply chain and support its broader “in-region, for-region” manufacturing approach.
For India, the project is significant because it adds higher-value manufacturing capabilities rather than simply expanding conventional pharmaceutical production. Biological buffers, specialty chemicals, stable isotopes and related materials are important inputs for pharmaceutical research, diagnostics, biotechnology and biopharmaceutical manufacturing.
Bengaluru’s Growing Life-Science and Advanced Manufacturing Ecosystem
The Jigani investment adds to Merck’s wider manufacturing footprint in Bengaluru. The company also operates its Peenya facility, which has been expanded with manufacturing capabilities for filtration hardware and systems used in bioprocessing and downstream purification.
This gives Bengaluru an increasingly diversified role in Merck’s India operations, spanning manufacturing, life-science applications, R&D and advanced technologies.
The Jigani site is particularly relevant because its capabilities connect specialty chemicals, biological materials, stable isotopes, analytical infrastructure and controlled distribution within one industrial location.
Employment and Industrial Impact
Merck has not disclosed a specific number of new jobs associated with the ₹140-crore-plus Jigani expansion, so an employment estimate would not be appropriate.
However, the investment is expected to deepen manufacturing capabilities and supporting activities around high-value life-science production. The addition of larger reactors, biological buffer manufacturing and expanded process-development capabilities also creates opportunities for suppliers, technical service providers, analytical laboratories, engineering companies and other specialised industrial partners.
Why the Investment Matters
Merck’s Bengaluru expansion reflects a broader shift in India’s pharmaceutical and life-science sector toward localised production of advanced inputs and technologies.
Rather than focusing only on finished medicines, investments such as this strengthen upstream and intermediate manufacturing capabilities that support:
- Pharmaceutical R&D
- Biopharmaceutical manufacturing
- Diagnostics
- Biotechnology
- Cell and molecular biology research
- Specialty and fine chemicals
- Advanced analytical applications
- Regional life-science supply chains
The project also demonstrates the growing role of India as a manufacturing and technology base serving not only the domestic market but customers across the Asia-Pacific region.
Merck’s Bengaluru Expansion: Key Takeaways
- ₹140+ crore investment planned by Merck KGaA.
- Investment value of approximately €13 million.
- Expansion located at the company’s Jigani facility in Bengaluru.
- Site has been operational since 2003.
- Facility occupies approximately 10 acres.
- New capability for biological buffer manufacturing.
- Expansion includes four 5,000-litre reactors.
- Annual buffer and fine-chemical capacity is stated at 100–300 MT.
- Existing site capabilities include specialty chemicals, fine chemicals, custom synthesis and catalogue products.
- Employment addition has not been publicly disclosed.
- The investment is intended to strengthen Merck’s India and Asia-Pacific manufacturing and supply chain network.
The Bigger Picture
Merck’s latest investment is another indication of India’s growing importance in the global life-science manufacturing ecosystem. The focus is increasingly moving beyond conventional pharmaceutical manufacturing toward specialised materials, biological manufacturing, process development and technologies supporting advanced therapies and diagnostics.
For Bengaluru, the expansion further strengthens the city’s position as a combined manufacturing, R&D and life-science technology hub. For Merck, the Jigani investment expands the company’s ability to serve regional customers while integrating Indian manufacturing into its global supply chain.
